Table 3 Treatment characteristics.

From: Association of mismatch repair status with survival and response to neoadjuvant chemo(radio)therapy in rectal cancer

Characteristics

MMR-proficient (n = 949)

MMR-deficient (n = 66)

NCT (n = 403)

NCRT (n = 546)

P value#

NCT (n = 21)

NCRT (n = 45)

P value#

Neoadjuvant chemotherapy regimen (%)

  

<0.001*

  

0.001*

 5FU/Xeloda

5 (1.2)

163 (29.9)

 

1 (4.8)

11 (24.4)

 

 FOLFOX/XELOX

314 (77.9)

360 (65.9)

 

15 (71.4)

34 (75.6)

 

 FOLFOXIRI

83 (20.6)

0 (0)

 

5 (23.8)

0 (0)

 

 Others

1 (0.2)

9 (1.6)

 

0 (0)

0 (0)

 

 NS

0 (0)

14 (2.6)

 

0 (0)

0 (0)

 

Adjuvant chemotherapy (%)

  

0.093

  

0.702

 Yes

355 (88.1)

460 (84.2)

 

18 (85.7)

40 (88.9)

 

 No

48 (11.9)

86 (15.8)

 

3 (14.3)

5 (11.1)

 
  1. 5FU 5-fluorouracil, FOLFOX 5-fluorouracil+oxaliplatin, XELOX xeloda+ oxaliplatin, FOLFOXIRI 5-fluorouracil+oxaliplatin+irinotecan, NS not sure.
  2. #Clinicopathological differences between the pMMR and dMMR groups stratified by neoadjuvant treatment groups were compared with the Mann–Whitney U test for continuous variables and χ2 test (or Fisher’s exact test, if appropriate) for categorical data.
Back to article page